Is lymph node positivity associated with disease recurrence in patients with small-bowel neuroendocrine tumors, and how many lymph nodes are needed to accurately stage patients undergoing curative resection?
This case series involving 199 patients who underwent curative-intent resection of a primary small-bowel neuroendocrine tumor found that lymph node positivity alone was not associated with disease recurrence; rather, a threshold of 4 positive lymph nodes was needed to see earlier disease recurrence. Retrieval of 8 or more total lymph nodes accurately discriminates recurrence-free survival in patients with 4 or more, 1 to 3, or 0 positive lymph nodes.
Having 4 or more positive lymph nodes is associated with earlier disease recurrence, and a minimum of 8 lymph nodes are needed to stage patients with small-bowel neuroendocrine tumors.
Little information is available regarding the minimum number of lymph nodes needed to accurately stage patients when performing a mesenteric lymphadenectomy for small-bowel neuroendocrine tumors.
To determine the prognostic role of lymph node positivity and the ideal number of lymph nodes for accurately staging patients with small-bowel neuroendocrine tumors.
Design, Setting, and Participants
This case series from the US Neuroendocrine Tumor Study Group, a collaboration among8 US-based, academic tertiary care referral centers, obtained demographic, perioperative, and pathologic data from the group’s database, Social Security Death Index, and publicly available obituaries. All patients in these institutions with small-bowel neuroendocrine tumors who underwent curative-intent surgical resection of a primary tumor between January 1, 2000, and December 31, 2015, were included (n = 199). Patients with duodenal or ampullary tumors, other nonneuroendocrine concurrent malignant neoplasms, mortality of fewer than 30 days after the surgical procedure, and distant metastatic disease were excluded. Data analysis was conducted from September 1, 2017, to December 1, 2017.
Main Outcomes and Measures
Primary study outcome was recurrence-free survival. Hypothesis was generated after data collection and data entry into the US Neuroendocrine Tumor Study Group database.
Of the 199 patients included, 112 (56.3%) were male and 87 (43.7%) female with a mean (SD) age of 60.3 (12.5) years and a mean (SD) body mass index of 29.5 (6.0). One hundred fifty-four patients (77.4%) had lymph node–positive disease. No difference in 3-year recurrence-free survival was found between patients with lymph node–positive and lymph node–negative disease. Patients with 4 positive lymph nodes had a worse 3-year recurrence-free survival compared with those with 1 to 3 or 0 positive lymph nodes (81.6% vs 91.4% vs 92.1%; P = .01). When examining patients with fewer than 8 resected lymph nodes, no difference in 3-year recurrence-free survival was observed among patients with 4 or more, 1 to 3, or 0 positive lymph nodes (100% vs 93.8% vs 91.7%; P = .87). Retrieval of 8 or more lymph nodes, however, accurately discriminated patients with 4 or more, 1 to 3, or 0 positive lymph nodes (3-year recurrence-free survival: 79.9% vs 89.6% vs 92.9%; P = .05).
Conclusions and Relevance
The findings from this study suggest that, for patients undergoing curative-intent resection of small-bowel neuroendocrine tumors, accurate lymph node staging requires a minimum of 8 lymph nodes for examination, and 4 or more positive lymph nodes are associated with decreased 3-year recurrence-free survival compared with 1 to 3 or 0 positive lymph nodes; a thorough regional lymphadenectomy may be critical for accurate staging and management of this disease.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zaidi MY, Lopez-Aguiar AG, Dillhoff M, et al. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surg. Published online October 31, 2018154(2):134–140. doi:10.1001/jamasurg.2018.3865
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: